IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this paper

Regolazione, innovazione e ciclo di vita dei prodotti - Per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica

Listed author(s):
  • Chiara Bonassi

    (Autorità Garante della Concorrenza e del Mercato)

  • Fabio Pammolli


    (Politecnico di Milano and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni


    (IMT Lucca Institute for Advanced Studies and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

  • Nicola Carmine Salerno


    (Ufficio parlamentare di bilancio)

All'indomani della pubblicazione della bozza di Finanziaria-2008, il Quaderno invita a riflettere su alcuni aspetti critici dell'articolo 5 in tema di spesa farmaceutica pubblica. L'analisi comparata delle dinamiche di settore/mercato induce a suggerire che: (a) le modalità di pricing al lancio distinguano chiaramente tra tipologie di prodotti (innovazioni significative, innovazioni incrementali, copie); (b) il pay-back segua regole meno discrezionali e distorsive di quelle proposte in Finanziaria; (c) maggior rilievo sia dato alla costruzione della cornice regolatoria (lato offerta e domanda) e al coordinamento Stato-Regioni nell'individuazione dell'agenda (non solo la responsabilizzazione finanziaria) e nella sua implementazione. Ci si augura che il Quaderno possa positivamente contribuire al dibattito lungo l'iter della Finanziaria.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL:
File Function: First version, 2007
Download Restriction: no

Paper provided by Competitività, Regole, Mercati (CERM) in its series Working Papers CERM with number 02-2007.

in new window

Length: 50 pages
Date of creation: Oct 2007
Handle: RePEc:ern:wpaper:02-2007
Contact details of provider: Postal:
Via Fiorentina, 1, 53100 Siena

Phone: +39 3476005404
Web page:

More information through EDIRC

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

in new window

  1. Patricia M. Danzon & Jonathan D. Ketcham, 2004. "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand," NBER Chapters,in: Frontiers in Health Policy Research, Volume 7, pages 1-54 National Bureau of Economic Research, Inc.
  2. J. Kornai & E. Maskin & G. Roland., 2004. "Understanding the Soft Budget Constraint," VOPROSY ECONOMIKI, N.P. Redaktsiya zhurnala "Voprosy Economiki", vol. 12.
  3. Patricia M. Danzon & Mark V. Pauly, 2002. "Health Insurance and the Growth in Pharmaceutical Expenditures," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 587-613.
  4. Fabio Pammolli & Nicola Carmine Salerno, 2007. "La distribuzione al dettaglio dei farmaci - Tra regolazione efficiente e mercato," Working Papers CERM 01-2007, Competitività, Regole, Mercati (CERM).
  5. James W. Hughes & Michael J. Moore & Edward A. Snyder, 2002. ""Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare," NBER Working Papers 9229, National Bureau of Economic Research, Inc.
  6. Drummond, Michael & Jonsson, Bengt & Rutten, Frans, 1997. "The role of economic evaluation in the pricing and reimbursement of medicines," Health Policy, Elsevier, vol. 40(3), pages 199-215, June.
  7. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
  8. Grabowski, Henry G & Vernon, John M, 1992. "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act," Journal of Law and Economics, University of Chicago Press, vol. 35(2), pages 331-350, October.
  9. Desmond Sheridan & Jim Attridge, 2006. "The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine," PharmacoEconomics, Springer, vol. 24(2), pages 35-54, December.
Full references (including those not matched with items on IDEAS)

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:02-2007. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Guido Bora`)

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.